Developer docs
API playgroundTry for free, no card

Search company profiles

SeqOne Genomics

Full company profile

uuid0000car

Namestring
SeqOne Genomics
Legal namestring
SeqOne S.A.S.
Websiteurl
seqone.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

SeqOne Genomics is a French healthtech company founded in 2017 in Montpellier that operates an AI-powered, cloud-based next-generation sequencing (NGS) bioinformatics platform for clinical genomic analysis. The platform processes raw sequencing data from FASTQ through BAM and VCF to annotated variants, transforming it into actionable clinical insights for molecular laboratories, hospitals, and reference diagnostics providers. The SeqOne Platform is CE-IVD Class C certified under the EU In Vitro Diagnostic Regulation (IVDR) and holds ISO 13485, ISO 27001, ISO 27701, and ISO 42001 certifications, supporting regulated clinical deployment in oncology and rare disease diagnostics across 30+ countries.

The product portfolio centers on the SeqOne Platform, the DiagAI explainable AI variant interpretation engine (transparent 0-100 scoring, validated to recover 98% of causal variants within the top 10 candidates on 565 Genomics England WGS cases), SeqOne Flow for LIMS and IT system automation, and a suite of specialty oncology modules including SomaCGP (comprehensive genomic profiling), SomaLBx (liquid biopsy), SomaMethyl (epigenetic methylation analysis), SomaHemato (IGHV/CLL), and SomaHRD (validated on the PAOLA-1 cohort with 95% concordance to Myriad MyChoice). The April 2025 acquisition of Life & Soft added multi-omics and ISO-certified sequencing services, and the September 2025 acquisition of Congenica contributed the Sapentia clinical decision support platform, bringing the combined entity to 160+ laboratories worldwide. GenomeAlert! provides automated monthly reevaluation of variants against ClinVar updates to maintain diagnostic accuracy over time.

SeqOne generates revenue primarily through a SaaS subscription model layered with pay-per-analysis usage-based pricing, supplemented by professional services for implementation, validation, and clinical interpretation, and channel/licensing arrangements such as the Arquimed partnership for Latin American distribution. The company combines an enterprise field sales motion for strategic hospital and reference lab accounts with a product-led growth motion offering free trial access via regional portals (Europe, US, Australia, Switzerland, UK). The company reports ARR of $9.5 million as of 2025, supports 1,000+ biologists and geneticists, and employs between 101 and 250 staff across offices in Montpellier, Paris, Cambridge (UK, Wellcome Genome Campus), and Wilmington, Delaware.

Short descriptiontext

SeqOne Genomics provides an AI-powered, IVDR-certified NGS bioinformatics platform for clinical genomic analysis in oncology and rare diseases. It serves 160+ laboratories across 30+ countries with explainable AI variant interpretation, LIMS-integrated workflow automation, and specialized oncology modules.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMontpellier, France
HQ citystring
Montpellier
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical genomics software, NGS bioinformatics platform, variant interpretation software, precision oncology analysis, rare disease genomics
Industry4 codes
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code2 codes
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services518210
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Genomics Bioinformatics Software
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1SaaS Platform Subscription
TypeSubscription Recurring
Description

Cloud-based genomic analysis platform with pay-per-analysis model. Transparent, flexible pricing with no hidden fees or volume constraints. Subscription-based access with tiered options.

seqone.com
2Usage-based Analysis
TypeUsage Based
Description

Pay-per-analysis pricing model allowing labs to pay based on actual genomic test volume processed.

seqone.com
3Professional Services
TypeProfessional Services
Description

Implementation support, training, technical onboarding, and specialized bioinformatics services including CNV/MSI/Methylation model generation, variant database migrations, and method validation support.

seqone.com
4Platform Licensing
TypeLicensing Royalties
Description

Platform licensing to channel partners like Arquimed for deployment to laboratories across regions.

tipranks.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Pricing details2 tiers
1Pay-per-analysis with no volume constraints
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Transparent, flexible pricing with no hidden fees. No volume constraints mentioned.

seqone.com
2Free trial access to platform
ModelFreemiumBilling cadenceMonthly
Notes

Get started for free option available for platform evaluation.

seqone.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

SeqOne Genomics provides a cloud-based AI-powered NGS bioinformatics platform that transforms raw next-generation sequencing data (FASTQ → BAM → VCF → annotated VCF) into clinically actionable insights for oncology and rare disease diagnostics. The platform combines the SeqOne Platform with DiagAI explainable variant prioritization, SeqOne Flow workflow automation, and a suite of specialized oncology modules (SomaCGP, SomaLBx, SomaMethyl, SomaHemato, SomaHRD) to support molecular labs, hospitals, and clinical genetics centers with CE-IVD Class C certified clinical reporting.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 98% of causal variants identified within top 10 candidates (validated on 565 Genomics England WGS cases)
+4 more records
Product overview1 text field

SeqOne Genomics offers a unified cloud-based AI-powered clinical genomics platform combining advanced bioinformatics pipelines, explainable AI decision support, and integrated workflow automation. The core SeqOne Platform processes NGS data from raw sequencing files through variant calling, annotation, and clinical interpretation. Key modules include DiagAI for explainable AI-powered variant prioritization with transparent scoring, SeqOne Flow for LIMS and IT system integration, and specialized oncology tools (SomaCGP, SomaLBx, SomaMethyl, SomaHemato, SomaHRD) for precision cancer diagnostics. The company expanded its portfolio through the September 2025 acquisition of Congenica, adding their Sapentia clinical decision support platform. All products are CE-IVD Class C certified under IVDR for clinical use in oncology and rare diseases.

Product and service6 records
1SeqOne Platform
CategoryClinical Genomics Bioinformatics Software
Description

Cloud-based AI-powered NGS bioinformatics platform for clinical genomic analysis in oncology and rare diseases, offering automated pipelines from FASTQ to annotated variants with CE-IVD Class C certification under IVDR. Wet-lab and sequencer-agnostic, supporting panels, exomes, and genomes across short and long-read sequencing.

2DiagAI
CategoryClinical Genomics Bioinformatics Software
Description

Explainable AI-powered variant interpretation system using a transparent DiagAI Score (0-100) for ranking genetic variants' disease-causing potential, combining pathogenicity prediction, phenotype matching, and expert-driven rules. Validated on 565 Genomics England WGS cases with 98% of causal variants within top 10 candidates.

3SeqOne Flow
CategoryWorkflow Automation Software
Description

Workflow automation engine that integrates with LIMS and IT systems via HL7/FHIR interfaces, automating data pipelines from file transfer to analysis initiation to eliminate manual work and speed up turnaround times.

4GenomeAlert!
CategoryClinical Genomics Bioinformatics Software
Description

Automated variant reevaluation agent that monthly reclassifies genetic variants against ClinVar updates to ensure accurate patient diagnoses and treatment decisions.

5Congenica
CategoryClinical Genomics Bioinformatics Software
Description

UK-based genomics analysis and clinical decision support platform acquired by SeqOne in September 2025, providing Sapentia technology and strengthening AI-powered genomic medicine offerings; combined entity serves over 160 laboratories across 30+ countries.

6Clinical Interpretation Services
CategoryProfessional Services
Description

Expert clinical interpretation services supporting molecular labs with genomic analysis, enabling delivery of actionable insights to clinicians and patients, including CNV/MSI/Methylation model generation, variant database migrations, and method validation support.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-01
Description

Partnership to deploy SeqOne's genomic interpretation platform to laboratories across Chile. Arquimed will integrate SeqOne's clinically validated platform into its portfolio of end-to-end healthcare solutions, expanding precision medicine capabilities in Latin America.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Acquisition of UK-based Congenica to strengthen position in AI-powered genomic medicine. Unified genomic analysis and clinical decision support technology. Combined entity serves 160+ laboratories across 30+ countries.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Strategic collaboration to advance liquid biopsy data analysis for oncology applications. Partnership combines Agilent's sequencing capabilities with SeqOne's AI-powered analysis platform for comprehensive liquid biopsy solutions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

Acquisition of Life & Soft to expand multi-omics capabilities and service offerings with ISO-certified sequencing platform.

5MGI Tech
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-06-01
Description

Partnership to develop end-to-end genomic analysis solutions, combining MGI's sequencing technology with SeqOne's AI-powered platform for integrated workflows.

seqone.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-03-01
Description

Partnership to support interpretation of Nanopore sequencing in clinical use. Delivers end-to-end genome nanopore sequencing solutions for clinical applications in rare disease and oncology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sophia Genetics offers an AI-powered clinical genomics platform (SOPHiA DDM) that analyzes NGS data for oncology, rare disease, and hereditary cancer customers. It is the closest direct competitor to SeqOne in serving molecular labs with multi-modal genomic interpretation.

TypeDirect peer
Description

Fabric Genomics (acquired by Illumina) provides AI-driven clinical genomic interpretation for rare disease and oncology, including the GEM and OPAL algorithms. It competes head-to-head with SeqOne's DiagAI and rare-disease workflows.

TypeDirect peer
Description

Velsera, formed from the merger of Seven Bridges and Pierian, operates a clinical genomics analysis and interpretation platform for hospitals, labs, and pharma. It directly competes with SeqOne in tertiary genomic analysis and clinical decision support.

TypeDirect peer
Description

BC Platforms provides a genomics data platform combining biobanking, NGS analysis, and clinical interpretation. It targets similar clinical and research lab customers as SeqOne, particularly in Europe.

TypeDirect peer
Description

Lifebit operates a federated cloud genomics platform for clinical and research genomics. It competes with SeqOne's cloud-based NGS analysis offering, particularly for translational and population genomics customers.

TypeDirect peer
Description

DNAnexus provides a cloud-based genomics data analysis and management platform used by clinical labs, hospitals, and biopharma. It is comparable to SeqOne's cloud NGS analysis infrastructure layer.

TypeBroad incumbent
Description

QIAGEN's Digital Insights business (including QCI Interpret and Ingenuity) provides clinical variant interpretation and bioinformatics tools as part of a broader sample-to-insight portfolio, directly competing with SeqOne while also leveraging QIAGEN's installed wet-lab base.

TypeBroad incumbent
Description

Illumina bundles DRAGEN secondary analysis and Emedgene clinical interpretation with its dominant sequencer footprint, making it a broad incumbent competitor to SeqOne in clinical genomics analysis.

9Tempus
TypeBroad incumbent
Description

Tempus combines molecular profiling, AI-driven analytics, and clinical decision support for oncology and rare disease. While broader than SeqOne (including its own lab), it overlaps in NGS interpretation and precision oncology.

TypeEmerging player
Description

Personalis offers a comprehensive genomic profiling platform (NeXT Personal) for oncology customers with its own lab plus analytics. It overlaps with SeqOne's oncology/SomaCGP and SomaLBx positioning in tumor profiling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SeqOne Genomics

Clinical Genomics Bioinformatics Softwareseqone.com

SeqOne Genomics provides an AI-powered, IVDR-certified NGS bioinformatics platform for clinical genomic analysis in oncology and rare diseases. It serves 160+ laboratories across 30+ countries with explainable AI variant interpretation, LIMS-integrated workflow automation, and specialized oncology modules.

What SeqOne Genomics does

SeqOne Genomics is a French healthtech company founded in 2017 in Montpellier that operates an AI-powered, cloud-based next-generation sequencing (NGS) bioinformatics platform for clinical genomic analysis. The platform processes raw sequencing data from FASTQ through BAM and VCF to annotated variants, transforming it into actionable clinical insights for molecular laboratories, hospitals, and reference diagnostics providers. The SeqOne Platform is CE-IVD Class C certified under the EU In Vitro Diagnostic Regulation (IVDR) and holds ISO 13485, ISO 27001, ISO 27701, and ISO 42001 certifications, supporting regulated clinical deployment in oncology and rare disease diagnostics across 30+ countries.

The product portfolio centers on the SeqOne Platform, the DiagAI explainable AI variant interpretation engine (transparent 0-100 scoring, validated to recover 98% of causal variants within the top 10 candidates on 565 Genomics England WGS cases), SeqOne Flow for LIMS and IT system automation, and a suite of specialty oncology modules including SomaCGP (comprehensive genomic profiling), SomaLBx (liquid biopsy), SomaMethyl (epigenetic methylation analysis), SomaHemato (IGHV/CLL), and SomaHRD (validated on the PAOLA-1 cohort with 95% concordance to Myriad MyChoice). The April 2025 acquisition of Life & Soft added multi-omics and ISO-certified sequencing services, and the September 2025 acquisition of Congenica contributed the Sapentia clinical decision support platform, bringing the combined entity to 160+ laboratories worldwide. GenomeAlert! provides automated monthly reevaluation of variants against ClinVar updates to maintain diagnostic accuracy over time.

SeqOne generates revenue primarily through a SaaS subscription model layered with pay-per-analysis usage-based pricing, supplemented by professional services for implementation, validation, and clinical interpretation, and channel/licensing arrangements such as the Arquimed partnership for Latin American distribution. The company combines an enterprise field sales motion for strategic hospital and reference lab accounts with a product-led growth motion offering free trial access via regional portals (Europe, US, Australia, Switzerland, UK). The company reports ARR of $9.5 million as of 2025, supports 1,000+ biologists and geneticists, and employs between 101 and 250 staff across offices in Montpellier, Paris, Cambridge (UK, Wellcome Genome Campus), and Wilmington, Delaware.

SeqOne Genomics firmographics

Firmographics
Name
SeqOne Genomics
Legal name
SeqOne S.A.S.
Website
https://seqone.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
SeqOne Genomics provides an AI-powered, IVDR-certified NGS bioinformatics platform for clinical genomic analysis in oncology and rare diseases. It serves 160+ laboratories across 30+ countries with explainable AI variant interpretation, LIMS-integrated workflow automation, and specialized oncology modules.
Ownership category
akta.pro rank

SeqOne Genomics industry classification

Industry
Product category
Clinical Genomics Bioinformatics Software
NAICS
Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518210), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Computer Programming, Data Processing, Etc. (7370), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAANAD
Molecular Tumor Boards & Clinical Interpretation Services
SECONDARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Clinical genomics software
  • NGS bioinformatics platform
  • Variant interpretation software
  • Precision oncology analysis
  • Rare disease genomics

Where SeqOne Genomics is headquartered

Location

Headquarters

HQ city
Montpellier
HQ country
France
HQ region
Europe

Offices4 records

Markets served

SeqOne Genomics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. SaaS Platform Subscription: Cloud-based genomic analysis platform with pay-per-analysis model. Transparent, flexible pricing with no hidden fees or volume constraints. Subscription-based access with tiered options.
  2. Usage-based Analysis: Pay-per-analysis pricing model allowing labs to pay based on actual genomic test volume processed.
  3. Professional Services: Implementation support, training, technical onboarding, and specialized bioinformatics services including CNV/MSI/Methylation model generation, variant database migrations, and method validation support.
  4. Platform Licensing: Platform licensing to channel partners like Arquimed for deployment to laboratories across regions.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goPay-per-analysis with no volume constraints
FreemiumMonthlyFree trial access to platform

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

SeqOne Genomics product offering

Product offering

Core offering

SeqOne Genomics provides a cloud-based AI-powered NGS bioinformatics platform that transforms raw next-generation sequencing data (FASTQ → BAM → VCF → annotated VCF) into clinically actionable insights for oncology and rare disease diagnostics. The platform combines the SeqOne Platform with DiagAI explainable variant prioritization, SeqOne Flow workflow automation, and a suite of specialized oncology modules (SomaCGP, SomaLBx, SomaMethyl, SomaHemato, SomaHRD) to support molecular labs, hospitals, and clinical genetics centers with CE-IVD Class C certified clinical reporting.

Product overview

SeqOne Genomics offers a unified cloud-based AI-powered clinical genomics platform combining advanced bioinformatics pipelines, explainable AI decision support, and integrated workflow automation. The core SeqOne Platform processes NGS data from raw sequencing files through variant calling, annotation, and clinical interpretation. Key modules include DiagAI for explainable AI-powered variant prioritization with transparent scoring, SeqOne Flow for LIMS and IT system integration, and specialized oncology tools (SomaCGP, SomaLBx, SomaMethyl, SomaHemato, SomaHRD) for precision cancer diagnostics. The company expanded its portfolio through the September 2025 acquisition of Congenica, adding their Sapentia clinical decision support platform. All products are CE-IVD Class C certified under IVDR for clinical use in oncology and rare diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • SeqOne Platform Cloud-based AI-powered NGS bioinformatics platform for clinical genomic analysis in oncology and rare diseases, offering automated pipelines from FASTQ to annotated variants with CE-IVD Class C certification under IVDR. Wet-lab and sequencer-agnostic, supporting panels, exomes, and genomes across short and long-read sequencing.
  • DiagAI Explainable AI-powered variant interpretation system using a transparent DiagAI Score (0-100) for ranking genetic variants' disease-causing potential, combining pathogenicity prediction, phenotype matching, and expert-driven rules. Validated on 565 Genomics England WGS cases with 98% of causal variants within top 10 candidates.
  • SeqOne Flow Workflow automation engine that integrates with LIMS and IT systems via HL7/FHIR interfaces, automating data pipelines from file transfer to analysis initiation to eliminate manual work and speed up turnaround times.
  • GenomeAlert! Automated variant reevaluation agent that monthly reclassifies genetic variants against ClinVar updates to ensure accurate patient diagnoses and treatment decisions.
  • Congenica UK-based genomics analysis and clinical decision support platform acquired by SeqOne in September 2025, providing Sapentia technology and strengthening AI-powered genomic medicine offerings; combined entity serves over 160 laboratories across 30+ countries.
  • Clinical Interpretation Services Expert clinical interpretation services supporting molecular labs with genomic analysis, enabling delivery of actionable insights to clinicians and patients, including CNV/MSI/Methylation model generation, variant database migrations, and method validation support.

Quantifiable outcome

  • 98% of causal variants identified within top 10 candidates (validated on 565 Genomics England WGS cases)
  • +4 more outcomes

Companies that use SeqOne Genomics

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles3 records

SeqOne Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability9 records

Feature10 records

SeqOne Genomics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • ArquimedcoreChannel Partner/ Reseller/ Distributor · 1 April 2026Partnership to deploy SeqOne's genomic interpretation platform to laboratories across Chile. Arquimed will integrate SeqOne's clinically validated platform into its portfolio of end-to-end healthcare solutions, expanding precision medicine capabilities in Latin America.
  • CongenicaflagshipStrategic or Co-development Partner · 1 September 2025Acquisition of UK-based Congenica to strengthen position in AI-powered genomic medicine. Unified genomic analysis and clinical decision support technology. Combined entity serves 160+ laboratories across 30+ countries.
  • AgilentcoreStrategic or Co-development Partner · 1 June 2025Strategic collaboration to advance liquid biopsy data analysis for oncology applications. Partnership combines Agilent's sequencing capabilities with SeqOne's AI-powered analysis platform for comprehensive liquid biopsy solutions.
  • Life & SoftcoreStrategic or Co-development Partner · 1 April 2025Acquisition of Life & Soft to expand multi-omics capabilities and service offerings with ISO-certified sequencing platform.
  • MGI TechcoreTechnology or Integration · 1 June 2024Partnership to develop end-to-end genomic analysis solutions, combining MGI's sequencing technology with SeqOne's AI-powered platform for integrated workflows.
  • Oxford Nanopore TechnologiescoreTechnology or Integration · 1 March 2024Partnership to support interpretation of Nanopore sequencing in clinical use. Delivers end-to-end genome nanopore sequencing solutions for clinical applications in rare disease and oncology.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

SeqOne Genomics competitors and assessment

Company assessment

Direct peers

  • Sophia Genetics: Sophia Genetics offers an AI-powered clinical genomics platform (SOPHiA DDM) that analyzes NGS data for oncology, rare disease, and hereditary cancer customers. It is the closest direct competitor to SeqOne in serving molecular labs with multi-modal genomic interpretation.
  • Fabric Genomics (Illumina): Fabric Genomics (acquired by Illumina) provides AI-driven clinical genomic interpretation for rare disease and oncology, including the GEM and OPAL algorithms. It competes head-to-head with SeqOne's DiagAI and rare-disease workflows.
  • Velsera (Seven Bridges / Pierian): Velsera, formed from the merger of Seven Bridges and Pierian, operates a clinical genomics analysis and interpretation platform for hospitals, labs, and pharma. It directly competes with SeqOne in tertiary genomic analysis and clinical decision support.
  • BC Platforms: BC Platforms provides a genomics data platform combining biobanking, NGS analysis, and clinical interpretation. It targets similar clinical and research lab customers as SeqOne, particularly in Europe.
  • Lifebit Biotech: Lifebit operates a federated cloud genomics platform for clinical and research genomics. It competes with SeqOne's cloud-based NGS analysis offering, particularly for translational and population genomics customers.
  • DNAnexus: DNAnexus provides a cloud-based genomics data analysis and management platform used by clinical labs, hospitals, and biopharma. It is comparable to SeqOne's cloud NGS analysis infrastructure layer.

Broad incumbents

  • QIAGEN Digital Insights: QIAGEN's Digital Insights business (including QCI Interpret and Ingenuity) provides clinical variant interpretation and bioinformatics tools as part of a broader sample-to-insight portfolio, directly competing with SeqOne while also leveraging QIAGEN's installed wet-lab base.
  • Illumina (DRAGEN / Emedgene): Illumina bundles DRAGEN secondary analysis and Emedgene clinical interpretation with its dominant sequencer footprint, making it a broad incumbent competitor to SeqOne in clinical genomics analysis.
  • Tempus: Tempus combines molecular profiling, AI-driven analytics, and clinical decision support for oncology and rare disease. While broader than SeqOne (including its own lab), it overlaps in NGS interpretation and precision oncology.

Emerging players

  • Personalis: Personalis offers a comprehensive genomic profiling platform (NeXT Personal) for oncology customers with its own lab plus analytics. It overlaps with SeqOne's oncology/SomaCGP and SomaLBx positioning in tumor profiling.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SeqOne Genomics social profiles

Digital presence

SeqOne Genomics compliance and trust

Trust signal

Compliance12 records

SeqOne Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SeqOne Genomics leadership team

Management profile

Number of profiles

Profiles4 records

SeqOne Genomics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

SeqOne Genomics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SeqOne Genomics M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SeqOne Genomics

What does SeqOne Genomics do?

SeqOne Genomics provides a cloud-based AI-powered NGS bioinformatics platform that transforms raw next-generation sequencing data (FASTQ → BAM → VCF → annotated VCF) into clinically actionable insights for oncology and rare disease diagnostics. The platform combines the SeqOne Platform with DiagAI explainable variant prioritization, SeqOne Flow workflow automation, and a suite of specialized oncology modules (SomaCGP, SomaLBx, SomaMethyl, SomaHemato, SomaHRD) to support molecular labs, hospitals, and clinical genetics centers with CE-IVD Class C certified clinical reporting.

Is SeqOne Genomics a public or private company?

SeqOne Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was SeqOne Genomics founded?

SeqOne Genomics was founded in 2017. It employs 101 to 250 people.

Where is SeqOne Genomics based?

SeqOne Genomics is headquartered in Montpellier, France, in the Europe region.

How does SeqOne Genomics make money?

Four revenue lines are on record. SaaS Platform Subscription is the primary driver. The others are usage-based Analysis, professional Services and platform Licensing.

Who are SeqOne Genomics's main competitors?

Direct peers on record are Sophia Genetics, Fabric Genomics (Illumina), Velsera (Seven Bridges / Pierian), BC Platforms, Lifebit Biotech and DNAnexus. Broad incumbents are QIAGEN Digital Insights, Illumina (DRAGEN / Emedgene) and Tempus. Personalis is listed as an emerging player.

Does SeqOne Genomics have an API?

Yes. SeqOne offers a public API enabling customer IT teams to integrate autonomously. The API supports analysis triggering, file upload/download, and is designed as a product with comprehensive documentation, SDKs, and sandbox environments. The platform also supports SeqOne Flow Premium for workflow automation including LIMS connectors and HL7/FHIR interfaces. Developer documentation is at Not specified.

What industry is SeqOne Genomics in?

SeqOne Genomics's product category is Clinical Genomics Bioinformatics Software. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 518210 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAI Disrupts HLA Typing for Transplantation: Investment Activity Accelerates as Genomic Matching Enters a New EraBCC Research released a Pulse Report on artificial intelligence's impact on human leukocyte antigen typing for transplant medicine, covering donor-recipient matching, registry operations, and clinical decision platforms. The report finds North America leads AI adoption, while Asia-Pacific, the Middle East and South America expand donor registries, and cites eGenesis, SeqOne, Okeiro and InformAI among investors. It flags GDPR, the EU AI Act, algorithmic bias and uneven digital infrastructure as risks.GlobeNewswireRising Precision Medicine Fuels AI in Genomics Market Growth: Industry to Reach $9.32 Billion by 2030The AI in genomics market is projected to grow from $1.51 billion in 2025 to $9.32 billion by 2030, driven by precision medicine adoption, AI-powered drug discovery, and declining DNA sequencing costs. A notable industry development includes SeqOne S.A.S. 's acquisition of Congenica in 2025, which strengthened its position in AI-powered genomic medicine, while Genomic Vision launched its FiberSmart AI platform for analyzing long DNA fibers. North America currently leads the market, though Asia-Pacific is identified as the fastest-growing region, with tariffs affecting imported genomic data processing hardware costs.GlobeNewswireRising Precision Medicine Fuels AI in Genomics Market Growth: Industry to Reach $9.32 Billion by 2030The AI in genomics market is projected to grow from $1.51 billion in 2025 to $9.32 billion by 2030, driven by increased availability of genomic datasets, reduced DNA sequencing costs, precision medicine adoption, and AI-powered drug discovery. The report identifies North America as the current market leader with Asia-Pacific as the fastest-growing region, while noting that tariffs are inflating costs for imported genomic data processing hardware. A notable industry development is SeqOne S.A.S. 's acquisition of Congenica in 2025, enhancing its global standing in AI-powered genomic medicine.YahooRising Precision Medicine Fuels AI in Genomics Market Growth: Industry to Reach $9.32 Billion by 2030The AI in genomics market is projected to grow from $1.51 billion in 2025 to $9.32 billion by 2030, driven by precision medicine adoption, AI-powered drug discovery, and declining DNA sequencing costs, with a CAGR of 43.7%. Notable developments include SeqOne S.A.S. 's acquisition of Congenica in 2025 and Genomic Vision's launch of the FiberSmart AI platform in March 2023, while North America currently leads the market and Asia-Pacific represents the fastest-growing region. Tariffs on imported genomic data processing hardware are affecting costs in North America and Europe while spurring regional hardware production and cloud infrastructure deployment.openPR.comAI in Genomics Market Overview, Key Trends, and Insights on Leading CompaniesThe AI in genomics market is projected to grow to $9.32 billion by 2030, with a compound annual growth rate of 43.7%, driven by advances in precision medicine, AI-driven drug discovery, and population genomics initiatives. In September 2025, France-based SeqOne S.A.S. acquired UK-based Congenica for an undisclosed amount to strengthen its position in AI-driven genomic medicine. Genomic Vision, a French biotechnology company, launched FiberSmart in March 2023, an AI-powered software for visualizing and analyzing long DNA fibers at high resolution.TipranksSeqOne Partners With Arquimed to Expand Clinical Genomics Access in ChileSeqOne has announced a partnership with Arquimed to deploy its genomic interpretation platform to laboratories across Chile, expanding precision medicine capabilities in the country. Arquimed, characterized as a leader in medical innovation, will integrate SeqOne's clinically validated platform into its portfolio of end-to-end healthcare solutions. The collaboration may enable SeqOne to diversify its geographic revenue streams into Latin America while supporting broader access to clinical genomic data interpretation in Chilean healthcare centers.TipranksSeqOne Showcases AI-Driven Precision Oncology Platform at AACRSeqOne is presenting its AI-driven precision oncology platform at the AACR conference in San Diego, featuring tools such as Somatic DiagAI for automated drug-variant association scoring, SomaLBx for liquid biopsy workflows, SomaMethyl for methylation analysis, and SomaCGP for comprehensive genomic profiling. The company is also conducting a poster session on Somatic DiagAI focused on supporting clinical decision-making in cancer genomics. The article suggests that if SeqOne's tools gain traction with clinicians and researchers, the company could see improved commercial adoption and stronger data partnerships in the precision oncology market.TipranksSeqOne Showcases Explainable AI Genomics Platform at AEGH 2026 ConferenceSeqOne is showcasing its AI-powered genomics platform at the AEGH 2026 genetics conference in Granada, demonstrating live software capabilities focused on variant interpretation for rare diseases and complex genomics. The company is positioning its platform around explainability and clinical workflow integration, featuring its DiagAI transparent scoring system for end-to-end diagnostics. The article suggests this visibility at a specialized industry event may signal continued commercial push in precision medicine and clinical genomics, potentially supporting future revenue growth if conference interactions convert into pilots or expanded deployments.TipranksSeqOne Showcases Explainable AI Genomics Platform at AEGH 2026SeqOne showcased its explainable AI genomics platform at the AEGH 2026 meeting in Granada, offering on-site demonstrations at Booth 33 focused on scaling diagnostic precision for labs. The platform features AI-powered variant interpretation for rare diseases and complex genomics, along with a DiagAI scoring system designed for clinical workflows targeting high-throughput diagnostics. The company appears to be positioning itself for regulatory-sensitive clinical diagnostics markets, with potential pipeline and competitive benefits if conference interest converts to commercial adoption.